Clinical trial

SAM-e for the Treatment of Depression in Patients With Parkinson's Disease

NCT00070941

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention SAM-e Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention oral escitalopram Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention placebo Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

SAM-e for the Treatment of Depression in Patients With Parkinson's Disease

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2, PHASE3

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2003-07-01

PhasePHASE2 / PHASE3

Conditions

Parkinson's Diseaseverified · MONDO: Parkinson disease

Depressionverified · MONDO: depressive disorder

Interventions

SAM-eDRUG

oral escitalopramDRUG

placeboDRUG

Sponsors & collaborators

NYU Langone Healthlead sponsor

National Center for Complementary and Integrative Health (NCCIH)collaborator

Office of Dietary Supplements (ODS)collaborator

Mapped research locations

New YorkNew York, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00070941 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.